

tration of benzodiazepines or anticholinergic drugs does not seem to be advisable in cases of akathisia, given the potential side effects of these medications.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2016.01.068>

FC65

Antipsychotic-induced tardive dyskinesia: The role of glutamatergic system

A. Boiko^{1,*}, S. Ivanova¹, A. Semke²

¹ Mental Health Research Institute SB RAMSci, Laboratory of Molecular Genetics and Biochemistry, Tomsk, Russia

² Mental Health Research Institute SB RAMSci, Department of Clinical Psychiatry, Tomsk, Russia

* Corresponding author.

Tardive dyskinesia (TD) occurs in 20–25% of patients with long-term antipsychotic therapy. Abnormalities in glutamatergic transmission are considered one of the key components of the pathogenesis of drug-induced side effects. Glutamate acts as excitotoxin under certain conditions and in excessive concentrations. Aim is to study the concentration of glutamate and analysis of single nucleotide polymorphisms (SNP) in genes coding the glutamate transporter and NMDA-receptors in schizophrenic patients with TD and without it.

The study group included 156 patients with schizophrenia receiving long-term antipsychotic treatment. Patients were divided into two groups: 63 patients with TD and 93 patients without it. Glutamate was determined in serum by spectrophotometric method. Determination of allelic variants of gene SLC1A2 (rs4354668) and GRIN2A (rs2650427, rs1969060) was performed by polymerase chain reaction in real-time.

We found a significant ($P < 0.05$) increase of the concentration of glutamate in patients with TD. Significant ($P < 0.05$) reduction in frequency of genotype GG of GRIN2A (rs1969060) and TT of SLC1A2 (rs4354668) were found in patients with TD in comparison to group without TD. In the study of glutamate concentration depending on the genotype GRIN2A (rs1969060) and genotype SLC1A2 (rs4354668) we observed a statistically significant change: elevated levels of glutamic acid identified with the heterozygous genotype in patients.

It is possible to suggest that reduction in frequency of these genotypes increases the risk of movement disorders due to the protective effect of these genotypes.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2016.01.069>

FC66

Cognitive function in female patients with schizophrenia and metabolic syndrome

A.C. Botis^{1,*}, I. Miclutia¹, N. Vlasin²

¹ University of Medicine and Pharmacy Cluj-Napoca, Psychiatry and pediatric psychiatry, Cluj-Napoca, Romania

² Emergency County Hospital Cluj-Napoca, Psychiatry, Cluj-Napoca, Romania

* Corresponding author.

Introduction The metabolic syndrome (MetS) and cognitive impairments, both related with poor outcomes in schizophrenia, are common in patients with this disorder. MetS has been associated with cognitive impairments in schizophrenia, but there is no general consensus regarding the description of various domains of neurocognition in patients with schizophrenia related to MetS.

Objectives The goal of this study was to assess cognitive functions in female patients with schizophrenia complicated by metabolic syndrome compared to those with schizophrenia without metabolic syndrome.

Methods Fifty-four female patients diagnosed with schizophrenia were divided into two groups: MetS group (MetS+) and non-MetS group (MetS-). Cognitive functioning were investigated using the Brief Assessment of Cognition in Schizophrenia (BACS).

Results Twenty-seven (52%) patients with schizophrenia met criteria for the MetS diagnosis. Mean age of patients was 40.80. Patients from MetS+ group performed significantly worse on verbal memory ($P = 0.005$), executive functions ($P = 0.028$) and motor speed ($P = 0.035$) as compared to MetS- group. Patients with schizophrenia who were hypertensive showed cognitive impairments in 2 domains of cognition: attention and speed of information processing ($P = 0.004$) and verbal fluency ($P = 0.001$). Patients with hypertriglyceridemia performed significantly worse on verbal memory ($P = 0.005$). Motor speed was associated with waist circumference ($P = 0.02$).

Conclusions At a mean age of 40 years old, female patients with schizophrenia and metabolic syndrome show difficulties in more domains of cognitive function compared to female patients with schizophrenia without metabolic syndrome. Our findings suggest a link between cognition and metabolic syndrome in female patients with schizophrenia.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2016.01.070>

FC67

Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia

A. El-Missiry

Ain Shams University, Neurology & Psychiatry, Cairo, Egypt

Background Medication non-adherence presents a considerable problem in patients with schizophrenia. Cognitive and executive functions can affect adherence. The association between medication non-adherence and cognitive impairment in schizophrenia is under investigated with limited and conflicting research data.

Purpose of the study To prospectively assess the rate of drug adherence among a sample of patients with schizophrenia and to compare the cognitive and executive functions between adherent and non-adherent patients.

Subjects and methods One hundred and nine patients with schizophrenia diagnosed according to the DSM-IV classification were initially assessed by the Wechsler Adult Intelligence Scale (WAIS), Wechsler Memory Scale-Revised (WMS-R) and Wisconsin Card Sorting Test (WCST) and six months later by the Brief Adherence Rating Scale (BARS).

Results Among the patients, 68.8% were non-adherent to their antipsychotic medication. Adherent patients (31.2%) had significantly higher mean scores for the total, verbal and performance IQ. Moreover, they had significantly higher mean scores in most of WMS subtests (orientation, information, verbal paired association, digit span, visual memory span), and higher mean scores for; total correct, conceptual level response, percentage and categories completed on the WCST subscales ($P < 0.0001$). Whereas the non-adherent group had higher mean scores in; trials administered, total errors, perseverative responses, and perseverative errors ($P < 0.0001$). In a step regression analysis, digit span, conceptualization, total and percentage of errors were putative predictors of non-adherence to antipsychotic medications.

Conclusion Cognitive deficits, especially verbal memory and executive functions were the strongest patients' related factors associated with non-adherence to medication. Psychiatrists should